US2022331485A1PendingUtilityA1

Disrupted cartilage products

82
Assignee: OSIRIS THERAPEUTICS INCPriority: Jul 11, 2012Filed: Jun 30, 2022Published: Oct 20, 2022
Est. expiryJul 11, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Dana YooJin-Qiang KuangJaime PadenScott A. MaxsonAlla DanilkovitchErasmo LopezSamson Tom
A61L 27/3608A61K 38/014A61L 27/54A61L 27/3683A61L 27/50A61L 27/3687A61L 27/3817A61L 27/3691A61L 27/3612A61L 2300/414A61L 27/3852A61L 27/56A61L 27/3654A61L 2430/06A61K 35/32A61L 27/24A61L 2300/64
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A cryopreserved cartilage product is disclosed. The cryopreserved cartilage product can include a partially digested cryopreserved natural cartilage collagen matrix isolated from a subject. The collagen matrix can include viable cells embedded within the collagen matrix that are native to the collagen matrix and that were embedded in the collagen matrix when the collagen matrix was isolated from the subject, at least 70% of the embedded cells native to the collagen matrix can be viable in the cryopreserved cartilage product, and the partially digested collagen matrix can retain interaction between the collagen matrix and the native cells.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A cryopreserved cartilage product comprising a partially digested cryopreserved natural cartilage collagen matrix isolated from a subject, wherein:
 the collagen matrix contains viable cells embedded within the collagen matrix that are native to the collagen matrix and that were embedded in the collagen matrix when the collagen matrix was isolated from the subject;   at least 70% of the embedded cells native to the collagen matrix are viable in the cryopreserved cartilage product; and   the partially digested collagen matrix retains interaction between the collagen matrix and the native cells.   
     
     
         2 . The cryopreserved cartilage product of  claim 1 , wherein the collagen matrix has a thickness of about 0.2 mm to about 2.0 mm. 
     
     
         3 . The cryopreserved cartilage product of  claim 1 , wherein the collagen matrix has a thickness of about 1 mm to about 1.5 mm. 
     
     
         4 . The cryopreserved cartilage product of  claim 1 , wherein the viable cells native to the collagen matrix comprise viable chondrocytes. 
     
     
         5 . The cryopreserved cartilage product of  claim 1 , wherein the collagen matrix comprises a bioactive factor that is native to the collagen matrix. 
     
     
         6 . The cryopreserved cartilage product of  claim 1 , further comprising a cryopreservation medium. 
     
     
         7 . The cryopreserved cartilage product of  claim 1 , wherein the cartilage product is devoid of subchondral bone or calcified cartilage. 
     
     
         8 . The cryopreserved cartilage product of  claim 1 , wherein the cartilage product is depleted of immunogenic cells. 
     
     
         9 . The cryopreserved cartilage product of  claim 1 , wherein the cartilage product does not comprise macrophages. 
     
     
         10 . The cryopreserved cartilage product of  claim 1 , further comprising a layer of bone, wherein the layer of bone is native to the collagen matrix. 
     
     
         11 . The cryopreserved cartilage product of  claim 1 , wherein the partially digested collagen matrix is substantially intact relative to an undigested collagen matrix. 
     
     
         12 . The cryopreserved cartilage product of  claim 1 , wherein the partially digested collagen matrix comprises extracellular matrix protein fragments. 
     
     
         13 . The cryopreserved cartilage product of  claim 1 , wherein the collagen matrix comprises a cartilage layer that includes a radial layer, a transitional layer, or a tangential layer. 
     
     
         14 . The cryopreserved cartilage product of  claim 13 , wherein the collagen matrix comprises a plurality of channels. 
     
     
         15 . The cryopreserved cartilage product of  claim 14 , wherein the plurality of channels extend entirely through the radial, transitional, or tangential layer. 
     
     
         16 . The cryopreserved cartilage product of  claim 14 , wherein the plurality of channels have a cylindrical shape. 
     
     
         17 . The cryopreserved cartilage product of  claim 14 , wherein the collagen matrix comprises a channel density of about 10 to about 100. 
     
     
         18 . The cryopreserved cartilage product of  claim 14 , wherein the plurality of channels have a diameter of about 0.6 mm to about 1 mm. 
     
     
         19 . A method of treating an injured tissue in a subject, the method comprising removing the injured tissue and administering a thawed cryopreserved cartilage product of  claim 1  to the site where the injured tissue was removed. 
     
     
         20 . The method of  claim 19 , wherein the injured tissue is articular cartilage.

Join the waitlist — get patent alerts

Track US2022331485A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.